First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

January 31, 2012

Conditions
Pertussis
Interventions
BIOLOGICAL

BPZE1

Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).

BIOLOGICAL

Placebo

Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).

Trial Locations (1)

171 76

Karolinska University Hospital, Solna

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

European Union

OTHER

collaborator

Swedish Institute for Infectious Disease Control

OTHER

collaborator

Innogenetics

UNKNOWN

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV